PEPGEN INC (PEPG) Stock Price, Forecast & Analysis
USA - NASDAQ:PEPG - US7133171055 - Common Stock
PEPG Key Statistics, Chart & Performance
The current stock price of PEPG is 4.66 USD. In the past month the price decreased by -9.16%. In the past year, price decreased by -28.09%.
PEPG Latest News, Press Relases and Analysis
PEPG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About PEPG
Company Profile
PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Company Info
PEPGEN INC
245 Main St, 2nd Floor
Cambridge MASSACHUSETTS US
Employees: 62
Phone: 17034568000
PEPGEN INC / PEPG FAQ
What does PEPGEN INC do?
PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
What is the current price of PEPG stock?
The current stock price of PEPG is 4.66 USD. The price increased by 2.87% in the last trading session.
Does PEPGEN INC pay dividends?
PEPG does not pay a dividend.
How is the ChartMill rating for PEPGEN INC?
PEPG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for PEPG stock?
12 analysts have analysed PEPG and the average price target is 8.67 USD. This implies a price increase of 86.05% is expected in the next year compared to the current price of 4.66.
Would investing in PEPGEN INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PEPG.
What is the outstanding short interest for PEPGEN INC?
The outstanding short interest for PEPGEN INC (PEPG) is 5.73% of its float.
PEPG Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PEPG. When comparing the yearly performance of all stocks, PEPG is one of the better performing stocks in the market, outperforming 96.47% of all stocks.
PEPG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PEPG. While PEPG seems to be doing ok healthwise, there are quite some concerns on its profitability.
PEPG Financial Highlights
Over the last trailing twelve months PEPG reported a non-GAAP Earnings per Share(EPS) of -2.96. The EPS increased by 9.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.79% | ||
| ROE | -136.2% | ||
| Debt/Equity | 0 |
PEPG Forecast & Estimates
12 analysts have analysed PEPG and the average price target is 8.67 USD. This implies a price increase of 86.05% is expected in the next year compared to the current price of 4.66.